Please wait...

Learn

Finding accredited CPD

Current and emerging medications for the management of obesity in adults

Description

The prevalence of obesity among adults has nearly tripled worldwide since 1975 to more than 650 million in 2016, including 31% of adults in Australia. Obesity is the second leading contributor to Australia's burden of disease due to its complications, which include cardiovascular disease, type 2 diabetes, chronic kidney disease, fatty liver, obstructive sleep apnoea, and several cancers.

Many of these complications can be prevented or mitigated with a loss of as little as 5% of total body weight, with greater weight loss usually resulting in progressive improvements in obesity‐related complications and quality of life.

This MJA narrative review shares more.


Learning Outcomes

  1. Explain key components of the article
  2. List main findings
  3. Recognise the long-term approach of type-2 diabetes medicines in sustaining the health benefits of patients.

Details

Author: Rosalind Walmsley and Priya Sumithran

Article Type: Narrative Review

Provided by


CPD Activity Details
Topic
Pharmaceutical Preparations, Nutritional and Metabolic Diseases
CAPE Aspects
Professionalism
Effective Year

Educational Activities (EA) - 1.0

Reviewing Performance (RP) - 0.0

Measuring Outcomes (MO) - 0.0

You have to log in to see the content of this module.

*Medical Board of Australia’s (MBA)’s revised Registration Standard: Continuing professional development (the Standard)